We have discovered, profiled and patented three series of novel anti-invasive small molecules with potential as first-in-class therapeutic agents that in combination with antiproliferative drugs could substantially reduce morbidity and mortality in solid tumours with a high risk of metastasis. The mechanism of action of the compounds has been differentiated from that of compounds under development by others. A broad UGent consortium is focused on the preclinical progression of the current compounds to a point where they present commercial value and could be considered for clinical development. The aim of this Stepstone project is to generate a complementary range of drug discovery assets that will create an investable opportunity for a physical spin-off company capable of progressing our molecules towards the clinic.